TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06140303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SkinTE
Description: SkinTE is an Autologous Heterogeneous Skin Construct (AHSC), which is manufactured from a small piece of healthy full-thickness skin harvested from the patient at the time of randomization to the SkinTE arm. SkinTE is manufactured aseptically by PolarityTE following current Good Manufacturing Practice (cGMP). SkinTE is not cultured ex vivo; rather, it is returned to the provider expeditiously to maintain cellular viability. SkinTE includes various multicellular segments as a result of the manufacturing process. The different multicellular segments contain different types of skin cells, such as keratinocytes, dermal fibroblasts, dermal endothelial cells, and follicular cells, as well as extracellular matrix. The multicellular segments have a surface area-to-volume ratio for improved sustenance by imbibition prior to engraftment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard care is defined in this protocol to include the following:~* Debridement~* Collagen dressing~* Local offloading~* Foam~* Multi-layer compression dressing~* Off-loading device such as a controlled ankle motion (CAM) boot
Study: NCT05522101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-sized MCE
Description: AKES-31SW capsule endoscopy（Mini-sized MCE), its diameter is 9.5mm, length is 24.5mm, weight is 3.0g, shooting frequency is 0.5-6fps, image resolution is 480\*480, working time is not less than 8 hours. Mini-sized MCE is 0.6 times of traditional MCE in volume and weight, which is the smallest capsule in clinical application

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Normal-sized MCE
Description: Pillcam SB 3 capsule endoscopy（Normal-sized MCE), its diameter is 11.4mm, length is 26.2mm, weight is 3.0g, shooting frequency is 2-6fps, image resolution is 340\*340, working time is not less than 8 hours.
Study: NCT05843981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement TS III
Description: Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with TSIII Implant. . After osseointegration, dental implants will receive definitive prosthesis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant placement ks
Description: Implant placement in subjects who have lost at least two teeth and need a prosthetic implant rehabilitation with KS Implant. After osseointegration, dental implants will receive definitive prosthesis.
Study: NCT05939986

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality-based exposure treatment with multimodal feedback (VRET-M)
Description: The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality-based exposure treatment with multimodal feedback (VRET-M)
Description: The VRET-M group will experience visual, auditive and vibrotactile cues in the exposure sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality-based exposure treatment with bimodal feedback (VRET-B)
Description: The VRET-B group will experience visual and auditive cues in the exposure sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual reality-based exposure treatment with bimodal feedback (VRET-B)
Description: The VRET-B group will experience visual and auditive cues in the exposure sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Imagery exposure treatment (IET)
Description: The IET group will experience its own subjective imagined environment without any external stimulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery exposure treatment (IET)
Description: The IET group will experience its own subjective imagined environment without any external stimulation.
Study: NCT06224101

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Description: simulation training consists of practicing diagnostic coronary angiography with 3D printed simulator-SimulHeart.
Study: NCT04267367

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian-led dietary approach to management of diabetes
Description: In the intervention phase, the educational and diet plan package will be developed. All the intervention packages will be approved by a multi-disciplinary expert team comprising an endocrinologist and dietitian prior to the intervention. Patients in the usual care arm will receive routine care as to how he/she is practicing in their daily life. Routine care includes general knowledge on diabetes disease process, blood glucose monitoring, a healthy lifestyle, preventing treating diabetes complications and developing personalized strategies for the decision-making process\[27\]. The intervention package will include mainly two-phase, nutritional counseling emphasis on lifestyle modification of diabetes patients and individual basis diet plan for each T2DM patients for intervention arm. The nutrition education and counseling and individual diet plan will be applied by trained dietitians.
Study: NCT05059821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide cancer vaccine
Description: Vaccine content are personalized peptides vaccine separated from each patients own tumor cells, autologous heat shock protein 70 separated from tumor cells and autologous activated monocytes that administered subcutaneously monthly for six months
Study: NCT06283823

Intervention type: DEVICE
Intervention: Thermoformed orthodontic retainer
Description: compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers

Intervention type: DEVICE
Intervention: Thermoformed orthodontic retainer
Description: compare the outcome of the retaining phase of the orthodontic treatment with two different thermoformed retainers
Study: NCT04960930

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FMX101
Description: topically once daily
Study: NCT01970449

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)
Description: All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
Study: NCT04960930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FMX101
Description: topically once daily
Study: NCT04998539

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheelchair forward direction
Description: Participants will move the wheelchair over 5 meters of a soft surface (gym mats) in the forward direction. Participants will push the wheelchair when moving forward.
Study: NCT01737749

Intervention type: DEVICE
Intervention: Neurokeeper stroke detector
Description: Electrophisoloigcal monitoring
Study: NCT05780476

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: 6 sessions of 2 hours over 6 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation + virtual reality
Description: 6 sessions of 2 hours over 6 weeks. Virtual reality experience will be carry out in the last 30 minutes of each meeting. Virtual reality consists of 360-degree videos depicting everyday situations and allowing the caregivers to feel the specific symptoms of dementia (e.g., disorientation, agnosia, apraxia and memory loss).
Study: NCT06194760

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vitrectomy with ILM peeling
Description: Vitrectomy with traditional internal limiting membrane (ILM) peeling technique is regarded as the gold standard treatment for MH; it works by completely relieving of the traction of the macula and increasing the flexibility of the retina
Study: NCT03536052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Heart Guided Ablation
Description: If a good quality cardiac MRI is obtained and a virtual heart model with the ablation targets is generated, the operating physician will merge the virtual heart lesion map to the invasive electroanatomical navigation system. After the patient has been catheterized, an attempt should be made to induce VT. The physician should then navigate the catheter to each of the ablation targets specified, and place a lesion as per his or her training and experience, confirming when done that the lesion marker in the mapping system coincides with the target. This will be done for each lesion.
Study: NCT05351658

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KronoSafe® System
Description: All patients included in the study will have a temporary pacemaker with active fixation leads, held by the KronoSafe® fixation system.
Study: NCT05317338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based exercise training during hospitalization
Description: Multicomponent exercises for 5-7 days with acutely hospitalized older.
Study: NCT04577209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable oxygen face tent
Description: Disposable oxygen face tent used to minimize aerosol particles (through suction) during aerosol generating anesthesia procedures.
Study: NCT05130476

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-infrared-induced autofluorescence and indocyanine green near-infrared angiography
Description: During thyroid surgery, near-infrared-induced autofluorescence is used for the identification of the parathyroid glands, combined with indocyanine green near-infrared angiography for identification of the parathyroid feeding vessels.
Study: NCT06306534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory Nerve Acute (ANA) Electrode Array
Description: To measure eABRs when stimulating the human auditory nerve
Study: NCT05154461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alginate
Description: BHB covered in alginate will be realised in stomach-duodenum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pea-protein
Description: BHB covered in pea-protein will be released in ileum-colon
Study: NCT05659212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive IV dexmedetomidine 0.5 μg /kg diluted up to 10 ml with normal saline infused over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Patients will receive IV magnesium sulphate 50 mg/kg diluted up to 10 ml with normal saline infused slowly over 10 min before induction of anesthesia, and 10 ml of normal saline immediately before induction of anesthesia.
Study: NCT05328466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The engineer-built system, video-game based Kinect sensor
Description: The games were developed by the researcher team.
Study: NCT05659212

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive IV lidocaine 1.5 mg/ kg diluted up to 10 ml with normal saline immediately before induction of anesthesia and 10 ml of normal saline infused over 10 min before induction of anesthesia.
Study: NCT05620901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg, for intracanalicular use

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: To treat perioperative ocular inflammation and pain;
Study: NCT06209281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lower dose atropine sulfate eye drops
Description: Administer to eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine sulfate eye drops
Description: Administer to eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose atropine sulfate eye drops
Description: Administer to eyes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Administer to eyes
Study: NCT06548945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GZR18
Description: 5 mg-maximum tolerated dose (MTD), single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administered the same volume as GZR18
Study: NCT05868928

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging (MRI)
Description: Pre-and post-contrast enhanced T1-weighted image, T2-weighted image, fluid-attenuated inversion recovery image

Intervention type: DIAGNOSTIC_TEST
Intervention: Diffusion-weighted MRI
Description: Diffusion-weighted MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: Arterial spin labeling (ASL)
Description: Cerebral blood flow imaging parameter

Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic susceptibility contrast-MRI (DSC-MRI)
Description: Cerebral blood volume and vessel architectural imaging parameters
Study: NCT05452369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal plane block
Description: - 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal plane block
Description: - 30 mL bupivacaine 0.25% will injected ultrasound-guided in rhomboid intercostal fascial plane .
Study: NCT06463145

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanizem
Description: Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanizem
Description: Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanizem
Description: Aframomum melegueta seed extract standardized to 10% of total Vanilloid and at least 1.5% of 6-paradol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Food grade Maltodextrin 12
Study: NCT05850793

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sensorimotor Exercise
Description: Balance, perturbation , aging and strengthing exercise will be performed for knee

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensorimotor Exercise
Description: Balance, perturbation , aging and strengthing exercise will be performed for knee

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: Range of motion, strengthing and stretching exercise will be performed for knee

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Range of motion, strengthing and stretching exercise will be performed for knee

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional Exercise
Description: Range of motion, strengthing and stretching exercise will be performed for knee

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Motor Imagery Exercise
Description: Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Motor Imagery Exercise
Description: Different types of exercises will be applied targeting muscle strength, proprioceptive sense or brain neurons for knee
Study: NCT05216796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Intervention
Description: Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet Intervention
Description: Meal will be prepared and delivered by SNAP Kitchen, which has 7 locations in Austin and offers 20+ options for low-carbohydrate and low-calorie meals, each meal available in different sizes varying in energy intake. Meals will be entered into the Nutrition Data System for Research (NDS-R) software to confirm low-calorie profile. Meals will be delivered to participants' homes twice a week.
Study: NCT04693741

Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: secondary alveolar bone graft
Description: Under general anesthesia, the soft tissue in the gingiva surrounding the alveolar cleft will be injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. At the alveolar cleft site, gingival sulcus incisions will be made on both sides of the cleft. The tissue will then elevated beneath the periosteum. The mucosa of the nasal floor and the oral mucosa will be dissected. Next, the bone particles will be implanted into the bone defect.~Then, The cleft site will be closed without tension by the advancement of the gingival flaps.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Harvesting of the autogenous bone graft
Description: Under general anaesthesia ,the soft tissue in the superior iliac crest will injected with 0.5% lidocaine with 1:100,000 parts of epinephrine. The cancellous bone will harvested with an osteotome and then cut into small bone granules.
Study: NCT04931108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrendipine/Atenolol
Description: Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrendipine/Atenolol
Description: Nitrendipine/Atenolol 5mg/10mg single-pill combination, oral tablet, one pill daily.
Study: NCT04693741

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Preparation of PRP
Description: 10 ml of blood will be collected in vacuum tubes without anticoagulants which are then immediately centrifuged at a rate of 3000 rpm for 10 min. After centrifugation, the resultant product consists of three layers. The topmost layer consisting of acellular PPP (platelet poor plasma), PRF clot in the middle and RBCs at the bottom of the test tube. The attached red blood cells scraped off from it and discarded. The discarded PRF is then mixed with xenograft and placed inside the alveolar defect.
Study: NCT05782894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: 0\~2.0mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 0.3\~4.0mg/kg/h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: 1.5\~12μg/kg/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: 1.5\~12μg/kg/h
Study: NCT04931108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Description: Nitrendipine 5mg, oral tablet, one pill daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Description: Nitrendipine 5mg, oral tablet, one pill daily.
Study: NCT04726150

Intervention type: OTHER
Intervention: ILR implantation
Description: If LGE is present on CMR, ILR implantation will be proposed

Intervention type: OTHER
Intervention: ILR implantation
Description: If LGE is present on CMR, ILR implantation will be proposed

Intervention type: OTHER
Intervention: ILR implantation
Description: If LGE is present on CMR, ILR implantation will be proposed
Study: NCT06009237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-903
Description: Tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-903
Description: Tablet; oral
Study: NCT05476237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Therapy for Adolescents (IPT-AG)
Description: IPT-AG is a ten session, group therapy for adolescents. Each group contains 6-8 adolescents who attend weekly sessions together. The goals of IPT-AG are: 1) to reduce depression symptoms, and 2) to improve interpersonal relationships. Another aim of the group format is to increase adolescents' experience with positive social interactions and to reduce social isolation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Description: Adolescents will be administered unstructured psychotherapy in individual sessions with a trained mental health specialist (i.e., psychologist or psychiatric technician).
Study: NCT05725486

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-3 PUFAs Chicken Meet
Description: Intake of n-3 PUFAs enriched chicken meet for three weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regular Chicken Meet
Description: Intake of regular chicken meet for three weeks.
Study: NCT04907773

Intervention type: OTHER
Group type: OTHER
Intervention: Capillary blood sampling
Description: Each subject will have one to two capillary blood collections.

Intervention type: OTHER
Group type: OTHER
Intervention: Venous blood sampling
Description: Each healthy subject will also have a reference venous blood collection.

Intervention type: OTHER
Group type: OTHER
Intervention: Arterio-venous blood sampling
Description: Each hemodialysed subject will also have a reference arterio-venous blood collection.
Study: NCT05311995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only different trocar sites
Description: Only different trocar sites in literature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only different trocar sites
Description: Only different trocar sites in literature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only different trocar sites
Description: Only different trocar sites in literature

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only different trocar sites
Description: Only different trocar sites in literature
Study: NCT05894720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thrower's Ten Exercise Group
Description: the athletes were subjected to Thrower's Ten exercise program under the supervision of the same physiotherapist 3 days a week for a period of 6 weeks in addition to their routine practice programs.
Study: NCT04931108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol 25mg, oral tablet, one pill daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: Atenolol 25mg, oral tablet, one pill daily.